Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Mar 2017

Brant Roz, Sharpe Alan, Liptrot Tom, Dry Jonathan R, Harrington Elizabeth A, Barrett J Carl, Whalley Nicky, Womack Christopher, Smith Paul, Hodgson Darren R

Abstract excerpt

Purpose: To develop a clinically viable gene expression assay to measure RAS/RAF/MEK/ERK (RAS-ERK) pathway output suitable for hypothesis testing in non-small cell lung cancer (NSCLC) clinical studies.Experimental Design: A published MEK functional activation signature (MEK signature) that measures RAS-ERK functional output was optimized for NSCLC in silico NanoString assays were developed for the NSCLC optimized...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Computer Simulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Kinase Kinases

Share to MAP Kinase Signaling System

Share to Neoplasm Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to RNA, Small Interfering

Share to Transcriptome

Source

Identifiers

PMID: 27733477
DOI: 10.1158/1078-0432.CCR-16-0021

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors.PMID 27733477Read ↗

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.Semantic proximity Read ↗

Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Genetic predictors of MEK dependence in non-small cell lung cancer.Semantic proximity Read ↗

Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer.Semantic proximity Read ↗

Targeting MEK in non-small cell lung cancer.Semantic proximity Read ↗

Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer.Semantic proximity Read ↗

HER-3 Expression and MEK Activation in Non-small Cell Lung CancerSemantic proximity Read ↗

Functional measurement of mitogen-activated protein kinase pathway activation predicts responsiveness of RAS-mutant cancers to MEK inhibitors.Semantic proximity Read ↗

Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer.Semantic proximity Read ↗

Development of a High-Throughput Gene Expression Screen for Modulators of RAS-MAPK Signaling in a Mutant RAS Cellular Context.Semantic proximity Read ↗

HER3 expression and MEK activation in non-small-cell lung carcinomaSemantic proximity Read ↗

A systematic approach to therapeutic target selection in oesophago-gastric cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.